BR0013866A - Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos - Google Patents
Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicosInfo
- Publication number
- BR0013866A BR0013866A BR0013866-5A BR0013866A BR0013866A BR 0013866 A BR0013866 A BR 0013866A BR 0013866 A BR0013866 A BR 0013866A BR 0013866 A BR0013866 A BR 0013866A
- Authority
- BR
- Brazil
- Prior art keywords
- cationic liposomes
- distribution
- blood vessels
- taxane
- angiogenic blood
- Prior art date
Links
- 230000002491 angiogenic effect Effects 0.000 title abstract 4
- 239000002502 liposome Substances 0.000 title abstract 4
- 229940123237 Taxane Drugs 0.000 title abstract 2
- 210000004204 blood vessel Anatomy 0.000 title abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
"DISTRIBUIçãO DE LIPOSSOMAS CATIÈNICOS DE TAXANOS AOS VASOS SANGuìNEOS ANGIOGêNICOS". As células endoteliais angiogênicas são seletivamente alvejadas com complexos de lipídio/DNA ou lipossomas catiónicos contendo uma substância que afeta as células alvejadas através da inibição ou promoção de seu crescimento. Um local de angiogênese pode ser precisamente localizado através da administração de lipossomas catiónicos contendo um rótulo detectável. Os complexos podem compreender construções de nucleotideos que são compreendidas por promotores que são seletiva e exclusivamente ativados no ambiente de uma célula endotelial angiogênica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39297699A | 1999-09-09 | 1999-09-09 | |
PCT/US2000/024579 WO2001017508A1 (en) | 1999-09-09 | 2000-09-08 | Cationic liposome delivery of taxanes to angiogenic blood vessels |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013866A true BR0013866A (pt) | 2002-05-14 |
Family
ID=23552795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013866-5A BR0013866A (pt) | 1999-09-09 | 2000-09-08 | Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100226970A1 (pt) |
EP (1) | EP1210065B1 (pt) |
JP (2) | JP4848113B2 (pt) |
KR (1) | KR100591767B1 (pt) |
CN (1) | CN1235567C (pt) |
AT (1) | ATE324867T1 (pt) |
AU (1) | AU782714B2 (pt) |
BR (1) | BR0013866A (pt) |
CA (1) | CA2383412C (pt) |
CZ (1) | CZ2002850A3 (pt) |
DE (1) | DE60027730T2 (pt) |
EA (1) | EA005923B1 (pt) |
EE (1) | EE200200127A (pt) |
ES (1) | ES2258471T3 (pt) |
HK (1) | HK1046506B (pt) |
HU (1) | HUP0202669A3 (pt) |
IL (2) | IL148372A0 (pt) |
MX (1) | MXPA02002579A (pt) |
PL (1) | PL203128B1 (pt) |
WO (1) | WO2001017508A1 (pt) |
ZA (1) | ZA200201555B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6627201A (en) * | 2000-05-03 | 2001-11-12 | Mbt Munich Biotechnology Gmbh | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
WO2003028696A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
PT1509256E (pt) | 2002-05-24 | 2009-10-15 | Angiotech Int Ag | Composições e métodos de revestimento de implantes médicos |
EP1374864A1 (en) * | 2002-06-26 | 2004-01-02 | Munich Biotech AG | Amphiphilic taxane compositions |
EP1530465B2 (en) * | 2002-06-26 | 2015-12-16 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
CA2492080A1 (en) * | 2002-06-26 | 2004-01-08 | Medigene Oncology Gmbh | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
CA2542217C (en) * | 2003-10-15 | 2018-03-27 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
EP1711203A4 (en) | 2004-01-16 | 2007-06-13 | Barnes Jewish Hospital | TARGET TREATMENT OF ATHEROSCLEROSIS |
CA2601067A1 (en) | 2005-05-04 | 2006-11-09 | Medigene Ag | Method of administering a cationic liposomal preparation comprising paclitaxel |
RU2448697C2 (ru) | 2006-03-22 | 2012-04-27 | Медигене Аг | Лечение рака молочной железы, негативного по трем рецепторам |
WO2009111638A1 (en) | 2008-03-05 | 2009-09-11 | Baxter International Inc. | Compositions and methods for drug delivery |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
US9706903B2 (en) | 2009-06-18 | 2017-07-18 | Endochoice, Inc. | Multiple viewing elements endoscope system with modular imaging units |
DE102009032658A1 (de) * | 2009-07-09 | 2011-01-13 | Forschungszentrum Jülich GmbH | Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion |
KR101007925B1 (ko) * | 2009-10-07 | 2011-01-14 | 건일제약 주식회사 | 경구용 지질 나노입자 및 그의 제조방법 |
SG11201903326RA (en) * | 2016-10-28 | 2019-05-30 | Servier Lab | Liposomal formulation for use in the treatment of cancer |
KR102250123B1 (ko) | 2019-11-25 | 2021-05-10 | 주식회사 현대케피코 | 무단 변속기의 제한 목표 기어비 학습 방법 |
KR102261482B1 (ko) | 2019-12-10 | 2021-06-07 | 주식회사 현대케피코 | 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5092885A (en) * | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5192744A (en) * | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
DE69329073T2 (de) * | 1992-03-23 | 2001-01-18 | Georgetown University Washingt | In liposomen verkapseltes taxol und verwendungsverfahren |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
WO1994026254A1 (en) * | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
WO1994029288A1 (en) * | 1993-06-11 | 1994-12-22 | The Upjohn Company | Δ6,7-taxols antineoplastic use and pharmaceutical compositions containing them |
JP4850985B2 (ja) * | 1993-07-29 | 2012-01-11 | アメリカ合衆国 | 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法 |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5641755A (en) * | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
US5837682A (en) * | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
DE19605274A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln |
CZ297979B6 (cs) * | 1996-03-12 | 2007-05-16 | Pg-Txl Company, L. P. | Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka |
US5935937A (en) * | 1996-06-19 | 1999-08-10 | Fox Chase Cancer Center | Compositions and methods for inducing apoptosis |
US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
AU5646300A (en) * | 1999-02-10 | 2000-08-29 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of stimulating angiogenesis |
ATE493129T1 (de) * | 2001-10-30 | 2011-01-15 | Novartis Pharma Gmbh | Depot formulierungen von iloperidone und einem sternförmigen polymer |
-
2000
- 2000-09-08 PL PL354721A patent/PL203128B1/pl unknown
- 2000-09-08 ES ES00960004T patent/ES2258471T3/es not_active Expired - Lifetime
- 2000-09-08 JP JP2001521299A patent/JP4848113B2/ja not_active Expired - Lifetime
- 2000-09-08 DE DE60027730T patent/DE60027730T2/de not_active Expired - Lifetime
- 2000-09-08 EE EEP200200127A patent/EE200200127A/xx unknown
- 2000-09-08 CZ CZ2002850A patent/CZ2002850A3/cs unknown
- 2000-09-08 KR KR1020027003179A patent/KR100591767B1/ko active IP Right Grant
- 2000-09-08 MX MXPA02002579A patent/MXPA02002579A/es active IP Right Grant
- 2000-09-08 EA EA200200229A patent/EA005923B1/ru not_active IP Right Cessation
- 2000-09-08 IL IL14837200A patent/IL148372A0/xx active IP Right Grant
- 2000-09-08 WO PCT/US2000/024579 patent/WO2001017508A1/en active IP Right Grant
- 2000-09-08 EP EP00960004A patent/EP1210065B1/en not_active Expired - Lifetime
- 2000-09-08 HU HU0202669A patent/HUP0202669A3/hu unknown
- 2000-09-08 CA CA002383412A patent/CA2383412C/en not_active Expired - Lifetime
- 2000-09-08 AT AT00960004T patent/ATE324867T1/de active
- 2000-09-08 CN CNB008141339A patent/CN1235567C/zh not_active Expired - Lifetime
- 2000-09-08 BR BR0013866-5A patent/BR0013866A/pt not_active Application Discontinuation
- 2000-09-08 AU AU71229/00A patent/AU782714B2/en not_active Expired
-
2002
- 2002-02-25 IL IL148372A patent/IL148372A/en unknown
- 2002-02-25 ZA ZA200201555A patent/ZA200201555B/en unknown
- 2002-11-12 HK HK02108184.7A patent/HK1046506B/zh not_active IP Right Cessation
-
2010
- 2010-02-10 US US12/658,620 patent/US20100226970A1/en not_active Abandoned
- 2010-07-09 JP JP2010156449A patent/JP2010280667A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0013866A (pt) | Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos | |
BR9808018A (pt) | Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas | |
Loutrari et al. | Perillyl alcohol is an angiogenesis inhibitor | |
Taraboletti et al. | Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. | |
Wickstrom et al. | An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells | |
Cochard et al. | Cholinergic traits in the neural crest: acetylcholinesterase in crest cells of the chick embryo | |
Goldenberg et al. | Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178Y lymphoblasts | |
Coolican et al. | Effect of L-alpha-phosphatidylinositol on a vascular smooth muscle Ca2+-dependent protease. Reduction of the Ca2+ requirement for autolysis. | |
BR9805954A (pt) | Linhas de solução de auto-escorvamento e um método e sistema para usar as mesmas | |
Sugahara et al. | The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles | |
Philips | Compartmentalized signalling of Ras | |
TR200101539T2 (tr) | Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri. | |
FR2774588B1 (fr) | Composition cosmetique ou dermatologique contenant au moins une proteine de soie d'arachnides naturelle, recombinante ou un analogue | |
BR9813202A (pt) | Processo de administração de genes a células da pele que apresentam antìgenos | |
BRPI0113477B8 (pt) | proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula | |
BR0113928A (pt) | Polipeptìdio com uma sequência de aminoácidos, ácido nucléico, vetor, célula hospedeira, processo para a produção de polipeptìdeo e composição farmacêutica que contém uma quantidade farmaceuticamente efetiva do polipeptìdio | |
de Boer et al. | Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix | |
RU2222342C2 (ru) | Способы и композиции для модуляции ангиогенеза с использованием тирозинкиназы src | |
DE69929467D1 (de) | Modifizierte antikörper und antikörper-fragmente mit verlängerter aktivitätsdauer | |
Inestrosa et al. | A membrane-associated dimer of acetylcholinesterase from Xenopus skeletal muscle is solubilized by phosphatidylinositol-specific phospholipase C | |
Ofek et al. | Rational design of multifunctional polymer therapeutics for cancer theranostics | |
Gonzalez-Gronow et al. | Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts. | |
Choudhury et al. | Synthesis and DNA cleavage activity of a novel bleomycin A5 glycoconjugate | |
BR0009064A (pt) | Plantas apresentando capacidade reprodutiva modificada | |
Gasperi-Campani et al. | Mitochondrial DNA D-loop as a new target of Saporin 6 nuclease activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL: A61K 9/127 Ipc: A61K 9/127 (2009.01), A61K 31/337 (2009.01), A61P |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 13, 24 E 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |